Polish pharmaceutical group Polpharma, which has recently acquired the Romanian drug manufacturer Biofarm in a deal valued at about EUR257 million, says that Romania is one of its strategic markets for growth in Central and Eastern Europe and announces it will continue to invest in the Romanian company’s development.
Romania is approaching a decisive period for its economic credibility as key international assessments converge, prompting the American Chamber of Commerce in Romania (AmCham Romania) to call for faster implementation of structural reforms and stronger political commitment to the country’s economic agenda.